Navigation Links
Atherotech Unveils New Cardiometabolic Test Panels
Date:3/30/2009

Heart disease and diabetes markers to complement VAP advanced cholesterol profile

ORLANDO, Fla. and BIRMINGHAM, Ala., March 30 /PRNewswire/ -- Atherotech, Inc., developer of the VAP Cholesterol Test, has announced the addition of new cardiovascular and metabolic testing panels at ACC.09, the American College of Cardiology (ACC) 58th Annual Scientific Session Exposition. Atherotech is adding more than a dozen new tests, including C-Reactive Protein (hsCRP), ApoE genotype, and NT-proBNP, for assessment of patients at intermediate to high risk of cardiometabolic diseases. The company is also adding advanced and follow-up cardiovascular disease (CVD) risk profiles.

"We're maximizing the value of our core VAP technology with additional cardiometabolic tests," said Atherotech President Michael Mullen. "This provides physicians and cardiology practices with a single source for the VAP Cholesterol Test plus the new test panels. You get the complete cardiovascular and metabolic view."

Atherotech representatives will be available to discuss the VAP Cholesterol Test and new test panels in booth #1263, and blood draws will be provided to qualified attendees during exhibit hours March 29-31. Because LDL is directly measured, fasting is not required. Test results will be returned via mail after the conference.

The VAP Test, which recently added apoAI (and the apoB/apoAI ratio) to its panel, uses advanced lipid profile testing in the identification of individuals at increased risk of heart disease. The new test panels enable Atherotech to increase its scientific and diagnostic capabilities by offering much more complete cardiometabolic testing.

Steven Margolis, M.D., FAAFP, DABCL, a board-certified lipidologist who currently uses the VAP Test for advanced lipid testing of patients in his Sterling Heights, Mich., practice, says the new testing panels add significant benefits for practices such as his.

"It's very convenient for physicians to be able to get these heart disease risk factor tests grouped together and not have to deal with multiple reference labs," said Margolis. "They're also now offering specialized tests such as apoE genetic testing and NT-proBNP that aren't offered by most other reference laboratories."

The new test panels are available immediately and also include homocysteine, creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D, fibrinogen and insulin. The tests can be ordered individually, or bundled as part of a custom risk profile that may also include the VAP Test.

The VAP Test provides researchers and medical professionals with direct measurement of LDL, HDL and all relevant subclasses, and includes non-HDL, a highly accurate determination of apoB, and emerging risk factors such as Lp(a), remnants and small dense LDL. The VAP (Vertical Auto Profile) Test is now the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.

For more information call 877.901.8510 or visit www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando
2. Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
3. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
4. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
5. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
6. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
7. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
8. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
9. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
10. DNA 11 Unveils Modern-Day Family Portraits at The Museum of Science and Industry's Smart Home: Green + WIRED Exhibit
11. Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Germany , March 29, 2017 QIAGEN ... STANDARD: QIA) today announced the U.S. launch of its ipsogen ... cleared by the U.S. Food and Drug Administration as a qualitative in vitro ... extracted from EDTA whole blood.* ... ipsogen JAK2 assay is processed on QIAGEN,s Rotor-Gene ® Q MDx ...
(Date:3/29/2017)... TIKVAH, Israel , March ... (NASDAQ: BCLI), a leading developer of adult ... financial results for the year ended December ... highly successful and pivotal year for Brainstorm, with a ... made on clinical, regulatory and operational fronts," said ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a ... the world’s food supply through enhancement of the gut microbiota, today announced the closing ... Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a number of ...
Breaking Biology Technology:
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):